All In Biotech

Drug Trial Radar · NCT05961007

Evaluation of IBI302 Injection in nAMD or DME

A Dose Escalation Study to Evaluate the Safety and Tolerability of IBI302 Intravitreal Injection in Subjects With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema AND A Multi-center, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With Diabetic Macular Edema

Last checked: Nov 19, 2026Latest source record: Jul 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

SuspendedPivotal-lookingRandomized with 234 participants. This is a heuristic, not a regulatory label.

Status

Suspended

Enrollment

234

Planned (sponsor's estimate)

Start

Nov 18, 2021

Primary completion

Oct 31, 2023

Study completion Apr 30, 2024

Sponsor

Sponsor type
Industry
First posted
Jul 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the efficacy and safety of intravitreal IBI302 in the treatment of subjects with neovascular age-related macular degeneration (only in Phase I) or diabetic macular edema.

Conditions

  • Neovascular Age-related Macular Degeneration
  • Diabetic Macular Edema

Interventions

  • Intravitreal injection of IBI302(dose 1)Biological

    IBI302(dose 1) intravitreal injection given as protocol

  • Intravitreal injection of IBI302(dose 2)Biological

    IBI302(dose 2) intravitreal injection given as protocol

  • Intravitreal injection of IBI302(dose 3)Biological

    IBI302(dose 3) intravitreal injection given as protocol

  • Intravitreal injection of AfliberceptDrug

    Aflibercept intravitreal injection given as protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of ocular and non-ocular adverse events.Time frame: Up to week 20
  2. DLT in each groupTime frame: 7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.